This health-economic analysis investigated the cost, cost-effectiveness and cost-utility of intravenous paricalcitol compared with oral calcitriol and oral and intravenous alfacalcidol.

Patients were randomly assigned to receive oral paricalcitol or placebo. Dosing took place three times weekly, starting at 2 µ g or 4 µ g per dose (two trials) or once daily, starting at 1 µ g ...